Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 46.10 as of 2026-10-06T20:35:23.211Z.
Consensus retrieved: 2026-10-06T08:40:54.087Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:35:23.211Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5634534592ddc0dff26210766547620705b04d4b3456080b551355077da80429
Forward PE Ratio (46.10) = Dated Quote Price ($8.37) / Consensus Forward EPS ($0.18)
FORWARD PE RATIO
46.10
SECTOR MEDIAN · HEALTHCARE
19.79
median of 190 covered companies
CURRENT VS SECTOR MEDIAN
+133.00%
vs the sector median at left
Alignment Healthcare, Inc.
Market Cap
$1.74B
Forward PE Ratio
46.10
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alignment Healthcare, Inc. (ALHC) | $1.74B | 46.10 |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | N/A |
| Absci Corporation (ABSI)vs › | $1.74B | N/A |
| Novocure Ltd (NVCR)vs › | $1.74B | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 32.95 |
| Personalis, Inc. (PSNL)vs › | $1.71B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.59 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | N/A |
Trailing P/E
44.9
reported TTM EPS
Forward P/E
46.1
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.18 implies -5.3% EPS decline vs the reported trailing $0.19.
At the dated quote price of $8.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.18 | $0.16 – $0.20 | 6 | 46.1x |
| 2027-12-31 | $0.41 | $0.32 – $0.49 | 6 | 20.4x |
| 2028-12-31 | $0.68 | $0.44 – $0.87 | 8 | 12.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
